<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00310011</url>
  </required_header>
  <id_info>
    <org_study_id>CCCWFU-88197</org_study_id>
    <secondary_id>CDR0000466059</secondary_id>
    <secondary_id>CCCWFU-BG98-217</secondary_id>
    <secondary_id>AMGEN-CCCWFU-88197</secondary_id>
    <nct_id>NCT00310011</nct_id>
  </id_info>
  <brief_title>Gemcitabine, Paclitaxel, and Cisplatin in Treating Patients With Advanced Cancer of the Urothelium</brief_title>
  <official_title>A Phase II Trial of Gemzar (Gemcitabine), Taxol (Paclitaxel), and Platinol (Cisplatin) (GTP) in Treatment of Advanced Transitional Cell Carcinoma of the Urothelium</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as gemcitabine, paclitaxel, and cisplatin, work&#xD;
      in different ways to stop the growth of tumor cells, either by killing the cells or by&#xD;
      stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill&#xD;
      more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving gemcitabine together with paclitaxel&#xD;
      and cisplatin works in treating patients with advanced transitional cell cancer of the&#xD;
      urothelium.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine response to gemcitabine hydrochloride, paclitaxel, and cisplatin (GTP) among&#xD;
           patients with regional or distant metastases of transitional cell carcinoma of the&#xD;
           urothelium or local/regional recurrence after cystoprostatectomy.&#xD;
&#xD;
        -  Determine response in patients who receive GTP as the initial chemotherapeutic treatment&#xD;
           as well as in patients who have received prior chemotherapy.&#xD;
&#xD;
        -  Determine response duration, freedom from progression, and overall survival.&#xD;
&#xD;
        -  Assess the toxicity of GTP.&#xD;
&#xD;
      OUTLINE: This is an open-label study. Patients are stratified according to prior chemotherapy&#xD;
      (yes vs no).&#xD;
&#xD;
      Patients receive paclitaxel IV over 3 hours and cisplatin IV over 1 hour on day 1 and&#xD;
      gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days&#xD;
      for up to 4 courses in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients achieving a partial response or complete response undergo surgical restaging and&#xD;
      debulking. Four to 6 weeks later, patients receive 2 additional courses of chemotherapy.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 3 months for 1 year and then&#xD;
      every 6 months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 71 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 1998</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">October 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Response duration</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Freedom from progression</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity</measure>
  </primary_outcome>
  <enrollment type="Anticipated">71</enrollment>
  <condition>Bladder Cancer</condition>
  <condition>Transitional Cell Cancer of the Renal Pelvis and Ureter</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed transitional cell carcinoma (TCC) of the urothelium (bladder,&#xD;
             renal pelvis, or ureter) or TCC with squamous or glandular elements&#xD;
&#xD;
               -  No pure squamous cell carcinoma or adenocarcinoma&#xD;
&#xD;
          -  Disease not amenable to local curative treatment&#xD;
&#xD;
          -  Regional or distant metastases of TCC of the urothelium OR local/regional recurrence&#xD;
             after cystectomy, cystoprostatectomy, nephroureterectomy, or ureterectomy&#xD;
&#xD;
               -  If regional metastases present alone, histological confirmation of the metastases&#xD;
                  is required&#xD;
&#xD;
          -  No clinically evident brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0 or 1&#xD;
&#xD;
          -  Granulocyte count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 10 g/dL&#xD;
&#xD;
          -  Creatinine ≤ 1.6 mg/mL&#xD;
&#xD;
          -  Bilirubin ≤ 1.8 mg/mL&#xD;
&#xD;
          -  SGOT ≤ 3 times upper limit of normal&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  No known sensitivity to E. coli-derived products&#xD;
&#xD;
          -  No other prior or concurrent malignancy except active/inactive nonmelanoma skin&#xD;
             cancer, adequately treated stage I or II cancer currently in complete remission, or&#xD;
             observation-only early-stage prostate cancer&#xD;
&#xD;
          -  No other serious medical illness that would limit survival to &lt; 3 months&#xD;
&#xD;
          -  No psychiatric condition that would limit compliance with study requirements&#xD;
&#xD;
          -  No active uncontrolled bacterial, viral, or fungal infection unless corrected or&#xD;
             controlled&#xD;
&#xD;
          -  No hemorrhagic disorder&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior systemic chemotherapy regimen&#xD;
&#xD;
          -  Prior intravesical therapy allowed&#xD;
&#xD;
          -  Prior definitive radiation to renal pelvis, ureter, or bladder allowed&#xD;
&#xD;
          -  No concurrent chemotherapy with nonstudy drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank M. Torti, MD, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Carolinas Hematology-Oncology Associates</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203-4239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Cancer Center</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27403-1199</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Comprehensive Cancer Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157-1096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>March 29, 2006</study_first_submitted>
  <study_first_submitted_qc>March 29, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2006</study_first_posted>
  <last_update_submitted>August 8, 2018</last_update_submitted>
  <last_update_submitted_qc>August 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>metastatic transitional cell cancer of the renal pelvis and ureter</keyword>
  <keyword>recurrent transitional cell cancer of the renal pelvis and ureter</keyword>
  <keyword>transitional cell carcinoma of the bladder</keyword>
  <keyword>regional transitional cell cancer of the renal pelvis and ureter</keyword>
  <keyword>stage IV bladder cancer</keyword>
  <keyword>recurrent bladder cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Ureteral Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

